For research use only. We do not sell to patients.
Ionizable lipids / AMG1541
AMG1541 chemical structure
Product imageResearch use only
CAT. NO. DC67558Featured

AMG1541

Pack size & price

USD
Supporting components
DOPE DC33634 · 100 mg+Cholesterol DCD-041 · 100 mg+DMG-PEG2000 DC40169 · 100 mg

Components are supplied separately; this is not a premixed LNP. RNA/cargo, buffer and formulation service are not included.

Total$550
We match the best price and quality on market.
Ships from ShanghaiIce-pack transportPure lipid recommended
Product overview

Description & Application

AMG1541 is a degradable cyclic amino alcohol ionizable lipid studied for intramuscular mRNA delivery and influenza vaccine research. Its reported LNP formulation increased local reporter expression and antibody responses relative to the tested SM-102 formulation, while reducing liver reporter expression.

Open full Formulation & Performance →

Literature evidence · DC67558

Formulation & Performance

Reporter delivery, influenza antibody responses and short-term inflammatory measurements are presented as separate endpoints. Antibody dose-sparing is not a viral-challenge efficacy result.

The results below describe the cited research formulations. Product specifications and commercial pack options are shown in the Specifications and ordering sections.

Formulation components and molecular-weight conversion

ComponentDC Chemicals productMolecular weightMolar ratioMass at 1 µmol total lipid (mg)
AMG1541DC675581783.38350.624183
DOPEDC33634744.03160.119045
CholesterolDCD-041386.6546.50.179792
DMG-PEG2000DC4016925072.50.062675

AMG1541/DOPE/cholesterol/DMG-PEG2000 = 35:16:46.5:2.5 mol%. Ionizable lipid:mRNA = 10:1 by weight; the authors separately report N/P = 11.4:1. Source: Supplementary Table 1 (PDF p. 3). Component-mass calculations use the catalog molecular weights shown here; the reported N/P is not recalculated from them.

Component mass calculator

Prefilled proportions follow the source specified above. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.

ComponentMWMolar ratioMass (mg)Mass %
AMG1541——
DOPE——
Cholesterol——
DMG-PEG2000——

Formulation properties

ParameterAMG1541 LNP resultSource / context
Diameter / PDI85 nm / 0.107Supplementary Table 3, PDF p. 18; representative data, no SD or replicate count in the table.
Encapsulation efficiency67%Supplementary Table 3; do not substitute values from neighbouring AMG lipids.
Apparent LNP pKaApproximately 6.5TNS assay at 25 °C; formulation-dependent measurement.
Loading ratiosN/P 11.4:1; ionizable lipid:RNA weight ratio 10:1Supplementary Table 1; the two ratios are distinct quantities.

Reporter expression and tissue selectivity

ExperimentConditionsReported result
Mouse muscle FLucBALB/cJ mice; 1 µg mRNA IM; 6 h3.5-fold above the SM-102/DSPC comparator and 1.7-fold above cKK-E12 (Main Fig. 2c).
Liver reporter expressionMatched reporter comparison8.3-fold lower than the SM-102 formulation (Main Fig. 2f). This is expression, not measured lipid accumulation.
Human PBMC expressionThree donor lots; FLuc readout at 24 hAMG1541 exceeded the SM-102 comparator across the reported RNA-input range (Supplementary Fig. 11).

Influenza HA antibody response

ComparisonStudy designResult / boundary
Low-dose AMG1541 versus SM-102HA mRNA; IM days 0 and 21; day-35 antibody readout; female BALB/c mice, n = 50.01 µg AMG1541-LNP and 1 µg SM-102-LNP produced comparable binding and HAI responses in the reported comparison (Main Fig. 3).
Matched 1 µg mRNA doseDay-35 HA-specific antibody measurementsReported increases over SM-102: 15.8-fold in male BALB/c, 6.8-fold in female BALB/c and 5.8-fold in female C57BL/6 mice (Main Fig. 3).
Endpoint scopeBinding antibodies and haemagglutination inhibitionThe dose difference does not establish equivalent protection in a viral-challenge or clinical study.

Inflammatory response and tolerability

SettingObserved resultInterpretation
Post-boost mouse cytokinesMost measured cytokines were comparable; female-mouse IL-2 was approximately fivefold higherSix-hour post-boost sampling. Do not summarize all cytokines as unchanged.
Human PBMC cytokinesWith HA mRNA, measured cytokines were broadly comparable to the SM-102 comparator at 24 hIn vitro donor-cell evidence, not a clinical tolerability assessment.
Pharmacokinetic boundaryNo AMG1541-specific half-life is assigned in this reviewAn earlier source-data label referred to AMG1041; those values are not transferred to AMG1541.

Original study figures

Original Figures 2–4 and Supplementary Information — Original source figures.

References and source locations

  1. Rudra A, Gupta A, Reed K, et al. Degradable cyclic amino alcohol ionizable lipids as vectors for potent influenza mRNA vaccines. Nature Nanotechnology 20, 1831–1842 (2025). DOI: 10.1038/s41565-025-02044-6.
  2. Author manuscript, Figures 2–4 and Supplementary Tables 1/3.
CAS No.Not available
Chemical NameAMG1541
SynonymsAMG-1541，AMG 1541
SMILESCCCCCC/C=C\CCCC(=O)OCC(O)CN1CCN(CC(O)COC(=O)CCC/C=C\CCCCCC)CCN(CC(O)COC(=O)CCC/C=C\CCCCCC)CCN(CC(O)COC(=O)CCC/C=C\CCCCCC)CCN(CC(O)COC(=O)CCC/C=C\CCCCCC)CCN(CC(O)COC(=O)CCC/C=C\CCCCCC)CC1
FormulaC102H186O18N6
M.Wt1783.38
Purity>95% by ELSD-HPLC
StoragePure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
Shipping conditionShips from Shanghai. Pure lipid is stable during ice-pack transport.
Publication
  1. Rudra A, Gupta A, Reed K, et al. Degradable cyclic amino alcohol ionizable lipids as vectors for potent influenza mRNA vaccines. Nature Nanotechnology 20, 1831–1842 (2025). DOI: 10.1038/s41565-025-02044-6.
  2. Author manuscript, Figures 2–4 and Supplementary Tables 1/3.
Laboratory planning

Solution Calculators

The product molecular weight is prefilled when available and remains editable. Confirm solvent compatibility and solubility before preparation.

Calculators use the listed value 1783.38 g/mol, based on the neutral monoisotopic mass. The calculated average formula mass is 1784.63 g/mol; the MW inputs are editable to match your material and calculation convention.

Mass = concentration × volume × molecular weight
Enter any three values to calculate the fourth.
C₁V₁ = C₂V₂
Enter any three values to calculate the fourth.
Preparing stock solutions

Quick preparation table

Solvent volumes update from the molecular weight above.

Mass1 mM5 mM10 mM
10 mg5.6073 mL1.1215 mL560.73 μL
25 mg14.0183 mL2.8037 mL1.4018 mL
50 mg28.0366 mL5.6073 mL2.8037 mL
100 mg56.0733 mL11.2147 mL5.6073 mL
250 mg140.1832 mL28.0366 mL14.0183 mL

Need a different pack size or technical document?

Contact our team with the catalog number and requested quantity.

Contact us
Handling guidance

Shipping, storage and sampling

How is the lipid shipped, and how should I store it?
We generally ship the neat (undissolved) lipid compound rather than an ethanol solution. The neat lipid is stable during transport with ice packs, and shipments originate from Shanghai. Pure form: store at −20 °C for up to 1 year. In solvent: store at −80 °C for up to 6 months or at −20 °C for up to 1 month. Keep sealed and protected from light. Avoid repeated thaw cycles for best results.
Pure lipid or solution — which should I choose?
Pure lipid is generally more stable during shipping and storage, so we usually recommend the pure form. A solution in ethanol or chloroform can be supplied when required by your workflow. Tell us the intended application, solvent and target concentration so the most suitable format can be confirmed.
How should I measure a small amount of oily or viscous lipid?
Ionizable lipids are often oily liquids or viscous semisolids, so material can be lost during repeated weighing or transfer. For a small pack, dissolve the entire quantity and aliquot it volumetrically. For example, add 1 mL ethanol to 25 mg lipid to prepare a 25 mg/mL stock, then use a pipette to withdraw the required amount. For quantities above 100 mg, direct weighing with an analytical balance may be more practical. Always confirm solvent compatibility and solubility first.
Can you support formulation optimization and scale-up?
Yes. Share the RNA cargo, target tissue, administration route, formulation method and assay plan. Our team can discuss starting molar ratios, N/P ratio and scale-up requirements for research workflows.